T1	Participants 0 136	Flutamide-metformin plus ethinylestradiol-drospirenone for lipolysis and antiatherogenesis in young women with ovarian hyperandrogenism:
T2	Participants 160 178	low-dose flutamide
T3	Participants 411 493	young women with ovarian hyperandrogenism, a variant of polycystic ovary syndrome.
T4	Participants 757 783	3 months in young patients
T5	Participants 1146 1282	Fasting blood glucose, serum insulin, lipid profile, testosterone, adiponectin, and IL-6 were determined at baseline and after 3 months,
T6	Participants 1354 1404	Doppler assessment of ovarian arterial resistance.
T7	Participants 1489 1550	By comparison of 3-month changes between randomized subgroups
T8	Participants 1803 2095	low-dose flutamide is herewith identified as a pivotal component within a first contraceptive combination therapy that has been shown to attenuate the hypoadiponectinemia, ovarian vascular hyperresistance, lean mass deficit, and central adiposity of young women with polycystic ovary syndrome
T9	Participants 2159 2192	currently used in a contraceptive
